Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2019

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-             

 

 

 

---

In October 2019, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99,2 and 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit     No.		Description
Exhibit 99.1		Press release dated October 31, 2019: Sanofi Q3 well on track
Exhibit 99.2		Product Sales Statement, for the Product Sales Measuring Period Ended September 30, 2019
Exhibit 99.3		Press release dated October 29, 2019: Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

 

2

---

Exhibit Index

 

Exhibit     No.		Description
Exhibit 99.1		Press release dated October 31, 2019: Sanofi Q3 well on track
Exhibit 99.2		Product Sales Statement, for the Product Sales Measuring Period Ended September 30, 2019
Exhibit 99.3		Press release dated October 29, 2019: Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

 

3

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: October 31, 2019						SANOFI
				By		/s/ Alexandra Roger
				Name:		Alexandra Roger
				Title:		Head of Securities Law and Capital Markets

 

4